tirzepatide surpass Efficacy and safety of monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Diabetes Distilled: SURPASS-CVOT – Tirzepatide

| Thyroid monitoring and management | Important safety considerations | Frequently asked questions | Take home message You can take Wegovy (semaglutide) if you have an underactive thyroid (hypothyroidism) and your BMI is over 27

J Biol Chem (2000) 275:382734

Most patients notice appetite-suppressing effects within 35 days of reaching an active dose on the new medication, though peak weight loss may take 34 weeks to manifest

The SUMMIT trial (Packer et al, NEJM 2025) randomized 731 patients with HFpEF and obesity (mean BMI 38) to tirzepatide vs

While not a traditional fat burner, its ability to regulate insulin, reduce hunger, and improve body composition makes it a powerful addition to a weight loss or recomposition plan